Cost analysis of closed-system transfer devices in bortezomib handling in a Brazilian cancer center
Journal of Oncology Pharmacy Practice
Published online on February 16, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionMultiple myeloma (MM) is a common hematologic cancer treated with bortezomib, a 26S proteasome inhibitor supplied by the Brazilian Unified Health System (SUS). Limited post-reconstitution stability leads to drug waste, though studies suggest ...
IntroductionMultiple myeloma (MM) is a common hematologic cancer treated with bortezomib, a 26S proteasome inhibitor supplied by the Brazilian Unified Health System (SUS). Limited post-reconstitution stability leads to drug waste, though studies suggest ...